Asociación Española de Gastroenterologia (Spanish Gastroenterology Association) Gastroesophageal Reflux Disease Guideline - Prospective Study
NCT ID: NCT00697008
Last Updated: 2009-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease.
NCT01601379
Canadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With GERD
NCT00634023
Symptoms and Management Strategies in Gastroesophageal Reflux Disease (GERD)
NCT00768443
Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)
NCT00842387
Diagnosis and Response to Treatment Using a Reliable Gastroesophageal Reflux Disease (GERD) Questionnaire: An In Clinical Practice Study
NCT00963144
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GERD patients
Patients with typical GERD symptoms
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age above 18
* Subjects with typical GERD symptoms: predominant heartburn/regurgitation
* Naive patients or off PPI treatment in the last 2 months
Exclusion Criteria
* Patient not suitable to be treated following the AEG guidelines
* Concomitant treatment with NSAID, antiplatelet drugs
* Previous PPI failure
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Javier Zapardiel, MD
Role: STUDY_CHAIR
AZ SPAIN
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Badajoz, Badajoz, Spain
Research Site
Palma de Mallorca, Balearic Islands, Spain
Research Site
Barcelona, Barcelona, Spain
Research Site
Sabadell, Barcelona, Spain
Research Site
Viladecans, Barcelona, Spain
Research Site
Cadiz, Cadiz, Spain
Research Site
Jerez de la Frontera, Cadiz, Spain
Research Site
Cabra, Cordoba, Spain
Research Site
Córdoba, Cordoba, Spain
Research Site
Donostia / San Sebastian, Guipuzcoa, Spain
Research Site
Huelva, Huelva, Spain
Research Site
Huesca, Huesca, Spain
Research Site
A Coruña, La Coruna, Spain
Research Site
Santiago de Compostela, La Coru�a, Spain
Research Site
Madrid, Madrid, Spain
Research Site
Marbella, Malaga, Spain
Research Site
Málaga, Malaga, Spain
Research Site
Murcia, Murcia, Spain
Research Site
Verín, Orense, Spain
Research Site
Vigo, Pontevedra, Spain
Research Site
Oviedo, Principality of Asturias, Spain
Research Site
Seville, Sevilla, Spain
Research Site
Tarragona, Tarragona, Spain
Research Site
LA Cuesta de Arguijon, Tenerife, Spain
Research Site
Alzira, Valencia, Spain
Research Site
Valencia, Valencia, Spain
Research Site
Barakaldo, Vizcaya, Spain
Research Site
Bilbao, Vizcaya, Spain
Research Site
Zaragoza, Zaragoza, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-GES-DUM-2007/3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.